|Cell Line Name:||A2780|
|Keywords:||Human ovarian carcinoma|
|Cell Line Description:||The A2780 human ovarian cancer cell line was established from tumour tissue from an untreated patient. Cells grow as a monolayer and in suspension in spinner cultures. A2780 is the parent line to the cisplatin resistant cell line A2780 cis (ECACC catalogue no. 93112517) and the adriamycin resistant cell line A2780 ADR (ECACC catalogue no. 93112520).|
|Subculture Routine:||Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 3-6x10,000cells/cm² using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37°C.|
|Culture Medium:||RPMI 1640 + 2mM Glutamine + 10% Foetal Bovine Serum (FBS).|
|Depositor:||Dr T H Ward, Cell Culture Unit, Patterson Laboratories, Christie Hospital, Manchester|
|References:||Semin Oncol 1984;11:285; Cancer Res 1987;47:414|
|Additional Bibliography:||Barretina J, et al., 2012 The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 483(7391):603-7. PMID: 22460905.|
|Patents:||None specified by Depositor|
|Research Council Deposit:||No|
The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.
Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.